時間 | 主題 | 講者 | 座長 | 簡報 | 錄影 |
---|---|---|---|---|---|
13:30 ~ 13:35 |
Opening |
李建儀 |
|||
13:35 ~ 14:00 |
Comparative study between behavior therapy and behavior therapy plus mirabegron 50mg in sexually active men with bothersome OAB symptoms – A multicenter, randomized study |
林志杰 |
闕士傑, 莊燿吉 |
||
14:00 ~ 15:25 |
Mirabegron is more tolerable than solifenacin in Sjogren’s syndrome patients with OAB symptoms |
曾浩翔 |
鄒頡龍, 莊斐琪 |
||
14:25 ~ 14:50 |
Drug Utilization Patterns in Patients with Lower Urinary Tract Dysfunctions (LUTD) in Taiwan |
柳瑞明 |
鍾旭東, 陳崇鈺 |
||
14:50 ~ 15:15 |
Urine Biomarkers in LUTD |
江元宏 |
郭漢崇, 王炯珵 |
||
15:15 ~ 15:40 |
The effect of 2-carba-cyclic phosphatidic acid on treatment chronic cystitis rats |
陳進利 |
李偉嘉, 蒙恩 |
||
15:40 ~ 16:00 |
Break |
||||
16:00 ~ 16:25 |
Comparison of Thulium Laser Enucleation and conventional transurethral resection among BPH patients |
謝博彥 |
蔡曜州, 林友翔 |
||
16:25 ~ 16:50 |
Risk factors associated with prostate abscess management and outcome |
楊立宇 |
林威宇, 許毓昭 |
||
16:50 ~ 17:15 |
Prostate cancer risk during BPH medical treatment |
李思恩 |
阮雍順, 林子平 |
||
17:15 ~ 17:40 |
Outcome analysis after transurethral resection of prostate |
陳思如 |
吳俊賢, 余宏政 |
||
17:40 ~ 18:00 |
Closing |
廖俊厚 |